A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: Toxic effects and immunologic results

G. Melioli, M. R. Sertoli, M. Bruzzone, M. T. Nobile, R. Rosso, P. L. Percivale, A. Catturich, F. Badellino, N. Balletto, D. Civalleri, A. M. Machi', A. Galatska, L. Santi, L. Moretta

Research output: Contribution to journalArticle

Abstract

A phase I study to evaluate the use of i.p. infusion of recombinant interleukin-2 (rIL-2) was planned. The following dose levels were calculated: 0.1, 0.3, 1.0, 3.0 and 10 mg/m2/day for 14 days, but only the second levels were reached. In this trial the acute toxic effects at this dosage included cardiac ischemia, transient liver impairment and septic peritonitis. The maximum tolerated dose (MTD) was 0.3 mg/m2/day for 14 days. In addition, two patients developed peritoneal fibrosis. No objective responses were observed. Therefore, in order to explore the biological activity of low (nontoxic) doses, three patients (one untreated and two previously treated with rIL-2) were infused with 0.01 and 0.03 mg/m2/day for 7 days. Potentiation of cytolytic activities in peritoneal lymphocytes and activation of a lymphokine cascade in the ascitic fluid were observed at doses ranging from 0.03 mg/m2/day to 0.3 mg/m2/day. These findings in association with the toxic effects observed at the MTD suggest the use of the minimum effective dose for future locoregional immunotherapeutic protocols.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: Toxic effects and immunologic results'. Together they form a unique fingerprint.

  • Cite this

    Melioli, G., Sertoli, M. R., Bruzzone, M., Nobile, M. T., Rosso, R., Percivale, P. L., Catturich, A., Badellino, F., Balletto, N., Civalleri, D., Machi', A. M., Galatska, A., Santi, L., & Moretta, L. (1991). A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: Toxic effects and immunologic results. American Journal of Clinical Oncology: Cancer Clinical Trials, 14(3), 231-237.